BARDA and Sanofi Pasteur, the vaccines global business unit of Sanofi, are expanding their collaboration to develop a SARS-CoV-2 vaccine. The previously announced research for a COVID-19 vaccine using a recombinant DNA platform will accelerate into non-clinical studies and a Phase 1 clinical trial to demonstrate initial safety and efficacy of the vaccine candidate.
The recombinant DNA vaccine technology produces an exact genetic match to proteins of the virus. The protein’s DNA is combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens are separated and collected from these cells and purified to create working stocks of vaccine for advanced development.
The technology was developed with BARDA support to make millions of doses of vaccine quickly in an influenza pandemic, and Sanofi uses the platform for its FDA-licensed seasonal influenza recombinant vaccine.
Activities also include regulatory support and process development for manufacturing large scale manufacturing in the United States, and planning for advanced stage clinical trials. Vaccination is an effective means of reducing infections, reducing disease severity and saving lives in pandemics.
The following information has been provided by the company and does not indicate an endorsement by the U.S. government of the company or its products.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.